News Search Results
Oct 10, 2025, 12:35 ET Alamar Biosciences lance le test NULISAqpcr™ BD-pTau217 : une avancée dans la détection non invasive de biomarqueurs spécifiques au cerveau pour la recherche sur la maladie d'Alzheimer
de modification de la maladie. » Disponible en tant que test NULISAqpcr simple-plex ou au sein du panel multiplex NULISAseq™ CNS Disease Panel 120, le test BD-pTau217 soutiendra à la fois la recherche de découverte et la recherche translationnelle. Le flux de travail automatisé
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 10:32 ET Alamar Biosciences 推出 NULISAqpcr™ BD-pTau217 檢測：阿茲海默症研究的非侵入性兼腦部特定生物標記檢測的突破
的專利 NULISA™ 平台，為非侵入性樣本類型（例如：血漿、血清和乾血斑）提供前所未有的靈敏度和特異度。本研究檢測直接測量 CNS 衍生的 pTau217，毋須腦脊液 (CSF) 收集或正子斷層造影 (PET)，這免除現時於人口為本研究或縱向臨床試驗中廣泛採用的障礙。 Alamar Biosciences 創辦人、董事長兼行政總裁 Yuling Luo 博士表示：「NULISAqpcr BD-pTau217 檢測，重新定義 CNS 生物標記定量的可能。現在研究人員可透過從 Tau 週邊來源去除雜訊，而更早兼更準確地檢測有意義的大腦變化。」
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 09:00 ET Next-Generation AI-Driven SyncAR® Spine Receives FDA Clearance for Spine Surgery
surgery. Surgical Theater will premiere this updated platform at two major upcoming events: the Congress of Neurological Surgeons (CNS) Annual Meeting and the North American Spine Society (NASS) Annual Meeting, where global spine leaders will have the opportunity to experience its newest
More news about: Surgical Theater
Oct 10, 2025, 07:48 ET Alamar Biosciences lanza el ensayo NULISAqpcr™ BD-pTau217 para la investigación de la enfermedad de Alzheimer
terapias modificadoras de la enfermedad". Disponible como ensayo NULISAqpcr de plexo simple o dentro del panel multiplex NULISAseq™ CNS Disease Panel 120, el ensayo BD-pTau217 facilitará tanto la investigación de descubrimiento como la traslacional. Su flujo de trabajo automatizado permite
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:45 ET Alamar Biosciences、非侵襲的かつ脳特異的なアルツハイマー病研究用バイオマーカー検出における革新技術「NULISAqpcr™ BD-pTau217アッセイ」を発表
を検出するうえで大きな可能性を示しており、疾患修飾療法の臨床試験候補者を特定する手がかりとなる可能性があります。」 BD-pTau217アッセイは、シングルプレックスのNULISAqpcrアッセイとして、またはマルチプレックスのNULISAseq™ CNS Disease Panel 120内の一部として提供され、創薬研究およびトランスレーショナルリサーチの双方を支援します。このアッセイの自動化ワークフローは、ARGO™ HT Systemを用いて1日に220検体以上を処理できるため、疾患コホートや集団ベース研究におけるハイスループット解析に最適です。
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:39 ET 알라마 바이오사이언스, NULISAqpcr™ BD-pTau217 분석법 출시: 알츠하이머병 치료를 목적으로 한 비침습적 뇌 내 바이오마커 검출 방식의 획기적인 진전
머지않아 연구 환경에서 다중 분석법으로 측정한 뇌 내 pTaus로 이런 환자의 병증을 검출할 수 있을 것으로 기대된다"라고 평했다. BD-pTau217 분석법은 신약 개발 혹은 중개 연구에 단일 검사 방식의 NULISAqpcr 분석법으로 사용하거나 다중 검사 방식의 NULISAseq™ CNS Disease Panel 120과 함께 사용할 수 있다. 이 분석법은 워크플로가 자동화되어 있어 ARGO™ HT 시스템으로 하루에 220개 이상의 검체를 처리할 수 있다. 따라서 코호트 연구나 다수를 대상으로 한 연구 목적으로 다량의 검체를 분석하는 데 이상적이다.
More news about: Alamar Biosciences, Inc.
Oct 10, 2025, 07:30 ET Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress
may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson
Oct 10, 2025, 05:38 ET CNS praises young Yemeni actor's perspective on "Rural China" in Shanghai
BEIJING, Oct. 10, 2025 /PRNewswire/ -- China News Service (CNS) issued a press release here on Friday to promote a young Yemeni actor's perspective on "Rural China"
More news about: China News Service (CNS)
Oct 09, 2025, 17:14 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. "The NULISAqpcr BD-pTau217 Assay redefines what's possible in CNS biomarker
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 16:54 ET Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research
measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials. "The NULISAqpcr BD-pTau217 Assay redefines what's possible in CNS biomarker
More news about: Alamar Biosciences, Inc.
Oct 09, 2025, 09:30 ET Monteris Medical and Symphony Robotics Announce Strategic Collaboration to Launch AI-Driven Micro-Robotic Platform for Laser Ablation in the Brain
major professional medical organizations including the American Association of Neurological Surgeons (AANS), the Congress of Neurological Surgeons (CNS), the American Association for Stereotactic and Functional Neurosurgery (ASSFN) and the National Comprehensive Cancer Network® (NCCN), Monteris has led
More news about: Monteris Medical
Oct 09, 2025, 07:52 ET Cadenza Bio Announces Peer-Reviewed Study Showing Oral, Brain-Penetrant ERβ Ligands Drive Remyelination and Functional Recovery in MS Models
Dosing: K102 and K110 achieved biologically relevant brain concentrations across species following oral administration, supporting their potential for CNS activity. "These findings highlight a novel dual mechanism of action supported by functional endpoints
More news about: Cadenza Bio, Inc.
Oct 09, 2025, 03:00 ET ARTHEx Biotech to Participate in Upcoming Investor and Industry Events
I/IIa ArthemiR™ trial. Building on this foundation, ARTHEx is advancing a pipeline of therapies for additional areas of high unmet need across muscular, CNS, and cardiac diseases. The Company headquarters are in Valencia, Spain. For more information on ArthemiR™,
More news about: ARTHEx Biotech
Oct 08, 2025, 21:00 ET 코헨 앤드 스티어스, DBS 뱅크와 손잡고 코헨 앤드 스티어스 다각화 실물 자산 펀드에 접근할 수 있는 기회 제공
https://www.cohenandsteers.com기호: NYSE: CNS
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 19:05 ET EMA Wellness Bolsters Executive Leadership to Scale its Market Leading Clinical Trial Platform
the heels of EMAW's continued global ascension as the new market standard in eCOA, digital data collection and integration and clinical analysis in CNS clinical trials. EMAW's web-based technology and singular code base drive the feature functionality of its proprietary GIANT™ platform. GIANT™ unifies
More news about: EMA Wellness
Oct 08, 2025, 16:42 ET Cohen & Steers, Inc. to Release Third Quarter 2025 Results on October 16, 2025
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release third quarter 2025 results after the market closes on Thursday, October 16, 2025. The earnings release and accompanying
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 16:28 ET Cohen & Steers Announces Preliminary Assets Under Management and Net Flows for September 2025
NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $90.9 billion as of September 30, 2025, an increase of $542 million from assets under management
More news about: Cohen & Steers, Inc.
Oct 08, 2025, 14:48 ET Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence
2025 Child Neurology Society (CNS) Annual Meeting, held in Charlotte, N.C. The company will present two new real-world evidence (RWE) posters and host a dedicated product theater
More news about: Theranica
Oct 08, 2025, 14:03 ET Phantom Neuro CEO Connor Glass to Present during BioFuture™ 2025
, CEO and founder Phantom Neuro, will present during a Spotlight Panel, " Rewiring Minds: Breakthroughs in Brain & CNS Health" (Spotlight Panel 1B). More information: This panel will be held on Monday, October
More news about: Phantom Neuro Inc.
Oct 08, 2025, 09:00 ET Neurelis to Highlight Data from a Study of Diazepam Nasal Spray in Pediatric Patients at the Child Neurology Society Annual Meeting
narrow-angle glaucoma Central Nervous System (CNS) DepressionBenzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating
More news about: Neurelis, Inc.
Oct 07, 2025, 09:00 ET Precision NeuroMed Granted FDA Orphan Drug Designation by U.S. FDA for Treatment of Glioblastoma Multiforme (GBM)
PNM), a clinical-stage biotechnology company pioneering advanced drug delivery technologies for central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its investigational therapy for glioblastoma
More news about: Precision NeuroMed
Oct 07, 2025, 08:30 ET Boosting clinical trial success in Alzheimer's, Parkinson's and other neurodegenerative diseases, Upcoming Webinar Hosted by Xtalks
efficiency of clinical trials for neurodegenerative diseases. The featured speakers will discuss strategies for integrating biomarkers into early-phase CNS clinical trials to improve patient diagnosis and treatment evaluation. The speakers will also discuss best practices to improve the success rates in
More news about: Xtalks
Oct 07, 2025, 08:00 ET GEMMABio Launches Rare Therapeutics, Inc. to Develop and Deliver Gene Therapies for Ultra‑Orphan Diseases
RareTx's portfolio is based on therapeutic platforms directed to monogenic disease that affect the central nervous system (CNS) or heart/skeletal muscle. The lead clinical-stage CNS programs include GM1 gangliosidosis ("GM1"), Krabbe disease ("Krabbe") and metachromatic leukodystrophy ("MLD"), ultra-orphan
More news about: GEMMA Biotherapeutics
Oct 07, 2025, 07:00 ET Peer AI Raises $12.1 Million to Accelerate Drug Approvals with an Intelligent Regulatory Workflow
CNS Summit to learn more and see a solution demo. About Peer AIPeer AI transforms regulatory
More news about: Peer AI
Oct 06, 2025, 08:30 ET Neuropsychiatry Clinical Trials: Evolving with Portable EEG and Digital Endpoints, Upcoming Webinar Hosted by Xtalks
In this free webinar, hear from CNS thought-leaders on the transformative power of objective measures of brain function in neuropsychiatry clinical trials. Attendees will gain insight into the power of EEG data synchronized with behavioural assessment data for
More news about: Xtalks